After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of EyePoint Pharmaceuticals Inc is $1.40B. A total of 1.93 million shares were traded on the day, compared to an average of 1.67M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, EYPT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 17 SELLs from insiders. Insiders purchased 4,000 shares during that period but sold 859,281.
In the most recent transaction, Jones David Scott sold 209 shares of EYPT for 28.49 per share on Feb 02. After the transaction, the SVP & Chief Commercial Officer now owns 37,962 company shares. In a previous transaction on Jan 26, Paggiarino Dario A. sold 49,325 shares at 25.66 per share. EYPT shares that Chief Medical Officer owns now total 36,505.
Among the insiders who sold shares, Jones David Scott disposed of 26,017 shares on Jan 26 at a per-share price of $25.38. This resulted in the SVP & Chief Commercial Officer holding 37,962 shares of EYPT after the transaction. In another insider transaction, Paggiarino Dario A. sold 600 shares at $25.00 per share on Jan 25. Company shares held by the Chief Medical Officer now total 36,505.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for EYPT in the last 3 months, the mean price target is $44.00 with high estimates of $68.00 and low estimates of $30.00. In terms of 52-week highs and lows, EYPT has a high of $30.99 and a low of $2.21.
As of this writing, EYPT has an earnings estimate of -$0.49 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.76. The company reported an EPS of -$0.61 in the last quarter, which was -201.70% lower than expectations of $0.6.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. EYPT’s latest balance sheet shows that the firm has $211.56M in Cash & Short Term Investments as of fiscal 2021. There were $39.20M in debt and $23.66M in liabilities at the time. Its Book Value Per Share was $1.66, while its Total Shareholder’s Equity was $184.38M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EYPT is Buy with a score of 5.00.
